


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:05:04Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406465" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406465</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>bmcpm</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Pulm Med</journal-id><journal-id journal-id-type="iso-abbrev">BMC Pulm Med</journal-id><journal-id journal-id-type="pmc-domain-id">64</journal-id><journal-id journal-id-type="pmc-domain">bmcpm</journal-id><journal-title-group><journal-title>BMC Pulmonary Medicine</journal-title></journal-title-group><issn pub-type="epub">1471-2466</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406465</article-id><article-id pub-id-type="pmcid-ver">PMC12406465.1</article-id><article-id pub-id-type="pmcaid">12406465</article-id><article-id pub-id-type="pmcaiid">12406465</article-id><article-id pub-id-type="pmid">40898117</article-id><article-id pub-id-type="doi">10.1186/s12890-025-03907-3</article-id><article-id pub-id-type="publisher-id">3907</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Impact of smoking on redox homeostasis and 8-OHdG levels in COPD patients: a cross-sectional comparative study</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>El Jundi</surname><given-names initials="O">Osman</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Uysal</surname><given-names initials="P">Pelin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dumur</surname><given-names initials="S">Seyma</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fenercioglu</surname><given-names initials="AK">Aysen Kutan</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Uzun</surname><given-names initials="H">Hafize</given-names></name><address><email>huzun59@hotmail.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02jqzm779</institution-id><institution-id institution-id-type="ISNI">0000 0004 7863 4273</institution-id><institution>Department of Chest Diseases, Faculty of Medicine, </institution><institution>&#304;stanbul Atlas University, </institution></institution-wrap>Istanbul, Turkey </aff><aff id="Aff2"><label>2</label>Department of Chest Diseases, Medicana Zincirlikuyu Hospital, Istanbul, Turkey </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02jqzm779</institution-id><institution-id institution-id-type="ISNI">0000 0004 7863 4273</institution-id><institution>Department of Medical Biochemistry, Faculty of Medicine, </institution><institution>&#304;stanbul Atlas University, </institution></institution-wrap>34403 Istanbul, Turkey </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01dzn5f42</institution-id><institution-id institution-id-type="GRID">grid.506076.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 1797 5496</institution-id><institution>Department of Family Medicine, Cerrahpasa Medical Faculty, </institution><institution>Istanbul University-Cerrahpasa, </institution></institution-wrap>Istanbul, Turkey </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>25</volume><issue-id pub-id-type="pmc-issue-id">478353</issue-id><elocation-id>423</elocation-id><history><date date-type="received"><day>27</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>14</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="12890_2025_Article_3907.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Chronic obstructive pulmonary disease (COPD) is a chronic and progressive condition that develops due to a genetic predisposition, with the dysfunction of antioxidants and anti-protease systems triggered by factors such as smoking. In this study, we aimed to determine the effects of smoking on serum 8-hydroxy-2&#8242; deoxyguanosine (8-OHdG) as a marker of oxidative DNA damage, malondialdehyde (MDA) to indicate lipid peroxidation, protein carbonyl (PCO) as a marker of protein damage, and paraoxonase (PON)1 levels as a measure of antioxidant activity involved in maintaining cellular redox balance in COPD patients.</p></sec><sec><title>Methods</title><p id="Par2">We conducted a cross-sectional study involving 141 patients with COPD (70 smokers, 71 non-smokers) and 140 healthy controls (70 smokers, 70 non-smokers) recruited from the Acibadem Mehmet Ali Aydinlar University outpatient clinic.</p></sec><sec><title>Results</title><p id="Par3">In the COPD-smokers group, significantly higher serum levels of 8-OHdG, MDA, and PCO, and a lower PON1 activity were found. A strong negative correlation was observed between 8-OHdG levels and both FEV1 and FEV1/FVC, as well as between 8-OHdG and PON1 activity in this group. ROC analysis demonstrated strong predictive power for 8-OHdG in the COPD-smokers group. However, given the study&#8217;s cross-sectional design and limited adjustment for confounders, these findings should be interpreted cautiously.</p></sec><sec><title>Conclusions</title><p id="Par4">These findings emphasize the critical importance of smoking cessation and antioxidant-targeted strategies in the clinical management of COPD. A systemic oxidant-antioxidant imbalance leads to impairment in the cellular redox homeostasis in patients with COPD and smokers. This study revealed that increased oxidative damage and reduced antioxidant defense in smoking COPD patients are associated with disease severity.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Chronic obstructive pulmonary disease</kwd><kwd>Malondialdehyde</kwd><kwd>Oxidative DNA damage</kwd><kwd>Paraoxonase</kwd><kwd>Protein carbonyl</kwd><kwd>Redox homeostasis</kwd><kwd>Smoking</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par24">Chronic obstructive pulmonary disease (COPD) is a progressive disorder influenced by genetic predisposition and characterized by impaired antioxidant and anti-protease systems, often triggered by smoking or environmental pollutants [<xref ref-type="bibr" rid="CR1">1</xref>]. Smoking is the primary global risk factor for COPD, associated with increased respiratory symptoms, accelerated decline in lung function (FEV1), and higher mortality compared to non-smokers [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par25">The lungs are highly susceptible to oxidative damage, which disrupts the extracellular matrix, membranes, and DNA, and impairs cellular functions [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Smoking induces an imbalance between oxidants and antioxidants, increasing oxidative stress in both smokers and COPD patients, thereby contributing to disease progression [<xref ref-type="bibr" rid="CR4">4</xref>&#8211;<xref ref-type="bibr" rid="CR17">17</xref>]. Reactive oxygen and nitrogen species (ROS and RNS) cause continuous DNA damage, producing multiple oxidative base modifications [<xref ref-type="bibr" rid="CR7">7</xref>]. Among these, 8-hydroxy-2&#8242;-deoxyguanosine (8-OHdG) is a sensitive biomarker of oxidative DNA damage, with plasma levels correlating to COPD severity and exacerbation risk [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par26">Reactive oxygen species (ROS) induce lipid peroxidation by oxidizing polyunsaturated fatty acids (PUFAs) in biological membranes, leading to the formation of malondialdehyde (MDA), a widely used biochemical marker of lipid damage in tissues [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. In addition to lipids, ROS also targets intracellular proteins, causing oxidative modifications that result in the formation of protein carbonyl (PCO) derivatives. These modifications compromise the structure and function of critical proteins, such as enzymes and cytoskeletal components, ultimately contributing to cellular dysfunction and damage. Due to their stability and specificity, PCO levels are commonly measured as reliable indicators of protein oxidation and overall oxidative stress in various pathological conditions [<xref ref-type="bibr" rid="CR12">12</xref>&#8211;<xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par27">Paraoxonase 1 (PON1) is a liver-synthesized enzyme belonging to the paraoxonase family. It plays a crucial role in defending the body against oxidative stress. It exhibits both antioxidant and anti-inflammatory properties, primarily by preventing lipid peroxidation and protecting low-density lipoprotein (LDL) cholesterol from oxidative modification, processes that contribute to atherosclerosis and other oxidative stress-related diseases. Unlike other paraoxonase isoforms, PON1 uniquely possesses arylesterase activity in addition to its paraoxonase function, allowing it to hydrolyze a wide range of substrates, including organophosphates and certain pharmaceuticals. Due to its multifunctional nature and significant impact on redox balance, PON1 is the most extensively studied and well-characterized enzyme within the paraoxonase family [<xref ref-type="bibr" rid="CR15">15</xref>&#8211;<xref ref-type="bibr" rid="CR18">18</xref>].</p><p id="Par28">Smoking-induced oxidant&#8211;antioxidant imbalance plays a key role in the pathogenesis and progression of COPD [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. This study aims to provide novel insights by simultaneously assessing oxidative stress markers (8-OHdG, MDA, PCO) and antioxidant enzyme activity (PON1) in smokers with COPD. Unlike previous studies focusing on individual parameters, this work examines their interrelations and associations with pulmonary function, offering mechanistic correlations. The objective is to clarify how smoking influences oxidative damage and antioxidant defense, and to evaluate the potential of 8-OHdG and PON1 as biomarkers for disease monitoring and therapeutic intervention.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Study population</title><sec id="Sec4"><title>Sample size and power analysis</title><p id="Par29">A priori power analysis was conducted using G*Power software (version 3.1.9.7) to estimate the required sample size. Based on previous studies evaluating oxidative stress biomarkers (e.g., 8-OHdG and PON1) in COPD patients, an effect size of 0.35 (moderate) was assumed for between-group comparisons (ANOVA). With a power (1&#8201;&#8722;&#8201;&#946;) of 0.80, a significance level (&#945;) of 0.05, and four independent groups (COPD-smokers, COPD-non-smokers, healthy smokers, healthy non-smokers), the minimum required total sample size was calculated to be 180 participants (approximately 45 per group). To account for potential dropouts or missing data, we increased the sample size to 281 participants, ensuring adequate statistical power for subgroup and correlation analyses.</p><p id="Par30">This prospective study included a total of 141 COPD cases who applied to Acibadem Mehmet Ali Aydinlar University, Faculty of Medicine outpatient clinic (COPD group) and 140 healthy cases (Control group). The COPD group was composed of 70 smokers and 71 non-smokers, and the control group was composed of 70 smokers and 70 non-smokers.</p></sec><sec id="Sec5"><title>Inclusion criteria</title><p id="Par31">We included COPD patients who had been diagnosed for at least one year and had stable disease for the past three months, with no changes in their medication regimen. The diagnosis of stable COPD was made following the GOLD guideline [<xref ref-type="bibr" rid="CR2">2</xref>], and only those who provided informed written consent were included in the study.</p></sec><sec id="Sec6"><title>Exclusion criteria</title><p id="Par32">We excluded patients with respiratory disorders other than COPD, including lung cancer, cystic fibrosis, asthma, pneumonia, tuberculosis, pulmonary emphysema, pulmonary embolism, and left ventricular systolic or diastolic dysfunction. Additionally, comorbidities such as diabetes, chronic renal insufficiency, thyroid dysfunction, hepatic dysfunction, metabolic syndrome, and lower respiratory tract infections were also considered. Patients with Asthma-COPD Overlap Syndrome (ACOS) and those using antilipidemic or antioxidant medications were excluded from the study.</p></sec></sec><sec id="Sec7"><title>Study design</title><p id="Par33">A comprehensive medical history was obtained from all participants, followed by a physical examination. The severity of COPD and associated comorbidities were recorded for each patient, and all participants underwent transthoracic echocardiography.</p><p id="Par34">Pulmonary function tests (PFT) were conducted on all patients who met the inclusion criteria, following the guidelines recommended by the European Respiratory Society (ERS). The tests were performed as soon as possible using a computer-assisted spirometer (Vmax22D, Sensor Medics, California, USA) by the same pulmonologist. Key pulmonary function parameters, including forced expiratory volume in 1&#160;s (FEV1), forced vital capacity (FVC), and the FEV1/FVC ratio, were measured during the stable phase of the disease. These patients exhibited stable airflow limitation, with FEV1&#8201;&lt;&#8201;80% of the predicted value, a FEV1/FVC ratio&#8201;&lt;&#8201;70% of the predicted value, and a post-bronchodilator reversibility of less than 12%.</p><p id="Par35">After an overnight fast, venous blood (10&#160;mL) was drawn from all volunteers at study entry before administration of the contrast agent or medications. Following centrifugation at 5000&#160;rpm for 15&#160;min, the serum was separated into four aliquots. The samples were then stored at &#8722;&#8201;80&#160;&#176;C until they were ready for biochemical analysis.</p></sec><sec id="Sec8"><title>Assessments</title><p id="Par36">Total protein, albumin, and uric acid levels were assessed using the spectrophotometric method by the autoanalyzer (Hitachi Modular System, Roche Diagnostic, USA). C-reactive protein (CRP) values were measured with the turbidimetric method by analyzer (ADVIA 1800 Auto Analyzer, Siemens Medical Sol., Deerfield, IL, USA).</p><p id="Par37">Serum 8-OHdG concentration was assessed using an enzyme-linked immunosorbent assay (ELISA) detection kit (OxiSelect&#8482; Oxidative DNA Damage ELISA Kit, Cat. No: STA-320; Cell Biolabs Inc., San Diego, CA, USA). MDA levels were measured using the methodology of Buege and Aust [<xref ref-type="bibr" rid="CR19">19</xref>], which is based on the measurement of the color produced during the reaction between thiobarbituric acid and MDA by spectrometry. PCO levels were assessed by the method of Reznick and Packer [<xref ref-type="bibr" rid="CR20">20</xref>] with minor revision. PON1 activity was assessed by monitoring the initial rate of substrate hydrolysis to p-nitrophenol, with absorbance measured at 412&#160;nm [<xref ref-type="bibr" rid="CR21">21</xref>]. The intra- and inter-assay coefficients of variation (CVs) for all parameters were calculated to be less than 10% (n&#8201;=&#8201;20) and less than 10% (n&#8201;=&#8201;20), respectively. All measurements were performed in duplicate to ensure reliability, and the laboratory personnel were blinded to the clinical status of the subjects to minimize bias. Internal quality control samples were included in each assay run to validate assay performance. There were no missing data for the biochemical parameters; all samples included in the analysis met predefined quality criteria.</p></sec><sec id="Sec9"><title>Statistical analysis</title><p id="Par38">All statistical analyses were conducted using SPSS version 22.0 (SPSS Inc., Chicago, IL, USA). Categorical variables are expressed as frequency (n), while continuous variables are presented as mean&#8201;&#177;&#8201;standard deviation or median (25th percentile&#8212;75th percentile), depending on the distribution. The Kolmogorov&#8211;Smirnov test was used to assess normality. The Chi-Square test was applied to compare categorical variables. For continuous variables, either the independent samples t-test or Mann&#8211;Whitney U test was used, depending on the normality of the data. The Kruskal&#8211;Wallis test was used for comparisons among four groups. To account for the increased risk of Type I error due to multiple group comparisons, the Bonferroni correction was applied. Adjusted p-values were interpreted, and only results meeting the corrected significance threshold were considered statistically significant. Spearman&#8217;s correlation test was employed to analyze relationships between laboratory parameters. The diagnostic value of parameters in COPD patients was assessed using receiver operating characteristic (ROC) curve analysis. A <italic toggle="yes">p</italic> value of less than 0.05 was considered statistically significant.</p></sec></sec><sec id="Sec10"><title>Results</title><sec id="Sec11"><title>Characteristics of the study populations</title><p id="Par39">The demographic characteristics and laboratory results of the study groups are summarized in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. No significant differences were observed in age and sex (<italic toggle="yes">p</italic>&#8201;&gt;&#8201;0.05). Laboratory data were collected for all participants included in the study.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>General demographic and laboratory characteristics of the total control and COPD groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Control (n&#8201;=&#8201;140)</th><th align="left" colspan="1" rowspan="1">COPD (n&#8201;=&#8201;141)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic></th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age (Year)</td><td align="left" colspan="1" rowspan="1">60.31&#8201;&#177;&#8201;5.217</td><td align="left" colspan="1" rowspan="1">61.16&#8201;&#177;&#8201;5.531</td><td align="left" colspan="1" rowspan="1">0.341<sup>a</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Sex (F/M)</td><td align="left" colspan="1" rowspan="1">65/75</td><td align="left" colspan="1" rowspan="1">66/75</td><td align="left" colspan="1" rowspan="1">0.152<sup>b</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">FEV1 (% predicted)</td><td align="left" colspan="1" rowspan="1">101 (96&#8211;106)</td><td align="left" colspan="1" rowspan="1">64 (37.5&#8211;80)</td><td align="left" colspan="1" rowspan="1"><bold>&#8201;&lt;&#8201;0.001</bold><sup>c</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">FEV1/FVC</td><td align="left" colspan="1" rowspan="1">83 (80&#8211;86)</td><td align="left" colspan="1" rowspan="1">65 (48&#8211;69)</td><td align="left" colspan="1" rowspan="1"><bold>&#8201;&lt;&#8201;0.001</bold>
<sup>c</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">CRP(mg/L)</td><td align="left" colspan="1" rowspan="1">0.3 (0.2&#8211;0.5)</td><td align="left" colspan="1" rowspan="1">0.4 (0.2&#8211;0.7)</td><td align="left" colspan="1" rowspan="1"><bold>0.005</bold>
<sup>c</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">ESR (mm/h)</td><td align="left" colspan="1" rowspan="1">8 (3&#8211;20)</td><td align="left" colspan="1" rowspan="1">18 (13&#8211;24.5)</td><td align="left" colspan="1" rowspan="1"><bold>&#8201;&lt;&#8201;0.001</bold>
<sup>c</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Triglyceride (mg/dL)</td><td align="left" colspan="1" rowspan="1">113 (95&#8211;177)</td><td align="left" colspan="1" rowspan="1">112 (90&#8211;166)</td><td align="left" colspan="1" rowspan="1">0.924 <sup>c</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">LDL (mg/dL)</td><td align="left" colspan="1" rowspan="1">107 (97&#8211;127)</td><td align="left" colspan="1" rowspan="1">131 (97&#8211;151.5)</td><td align="left" colspan="1" rowspan="1"><bold>0.017</bold>
<sup>c</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Total cholesterol (mg/dL)</td><td align="left" colspan="1" rowspan="1">173 (169&#8211;185)</td><td align="left" colspan="1" rowspan="1">201 (173.5&#8211;227.5)</td><td align="left" colspan="1" rowspan="1"><bold>&#8201;&lt;&#8201;0.001</bold>
<sup>c</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">HDL (mg/dL)</td><td align="left" colspan="1" rowspan="1">48.3 (42&#8211;54)</td><td align="left" colspan="1" rowspan="1">43.1 (39&#8211;51.5)</td><td align="left" colspan="1" rowspan="1"><bold>0.008</bold>
<sup>c</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Albumin (g/dL)</td><td align="left" colspan="1" rowspan="1">4.1 (4&#8211;4.2)</td><td align="left" colspan="1" rowspan="1">3.6 (3.3&#8211;3.9)</td><td align="left" colspan="1" rowspan="1"><bold>&#8201;&lt;&#8201;0.001</bold>
<sup>c</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">Total protein (g/dL)</td><td align="left" colspan="1" rowspan="1">8.1 (8&#8211;8.3)</td><td align="left" colspan="1" rowspan="1">7.3 (6.9&#8211;7.7)</td><td align="left" colspan="1" rowspan="1"><bold>&#8201;&lt;&#8201;0.001</bold>
<sup>c</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">8-OHdG (ng/mL)</td><td align="left" colspan="1" rowspan="1">3.6 (3.4&#8211;3.9)</td><td align="left" colspan="1" rowspan="1">5 (4.2&#8211;6)</td><td align="left" colspan="1" rowspan="1"><bold>&#8201;&lt;&#8201;0.001</bold>
<sup>c</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">MDA (nmol/mL)</td><td align="left" colspan="1" rowspan="1">2 (1.8&#8211;2.3)</td><td align="left" colspan="1" rowspan="1">3.1 (2.6&#8211;4)</td><td align="left" colspan="1" rowspan="1"><bold>&#8201;&lt;&#8201;0.001</bold>
<sup>c</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">PCO (nmol/mg.protein)</td><td align="left" colspan="1" rowspan="1">1 (0.9&#8211;1.5)</td><td align="left" colspan="1" rowspan="1">1.7 (1.2&#8211;1.9)</td><td align="left" colspan="1" rowspan="1"><bold>&#8201;&lt;&#8201;0.001</bold>
<sup>c</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">PON1 (U/mL)</td><td align="left" colspan="1" rowspan="1">90 (84.6&#8211;99.5)</td><td align="left" colspan="1" rowspan="1">61.5 (56&#8211;69.4)</td><td align="left" colspan="1" rowspan="1"><bold>&#8201;&lt;&#8201;0.001</bold>
<sup>c</sup></td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">FEV1</italic> forced expiratory volume, <italic toggle="yes">FEV1/FVC</italic> the ratio of FEV1 to forced vital capacity, <italic toggle="yes">CRP</italic> C-reactive protein, <italic toggle="yes">ESR</italic> erythrocyte sedimentation rate, <italic toggle="yes">HDL</italic> high density lipoprotein, <italic toggle="yes">LDL</italic> low density lipoprotein, <italic toggle="yes">8-OHdG</italic> 8-hydroxy-2&#8242;deoxyguanosine, <italic toggle="yes">MDA</italic> malondialdehyde, <italic toggle="yes">PCO</italic> protein carbonyl, <italic toggle="yes">PON1</italic> Paraoxonase 1</p><p>Data are presented as mean&#8201;&#177;&#8201;SD and median (25&#8211;75%). Significance of bold: *<italic toggle="yes">p</italic>&lt;0.05, **<italic toggle="yes">p</italic>&lt;0.001, <italic toggle="yes">p</italic>&lt;0.001</p><p><sup>a</sup>Independent samples t test</p><p><sup>b</sup>Chi-Square test</p><p><sup>c</sup>Mann-Whitney U test were applied</p></table-wrap-foot></table-wrap></p><p id="Par40">In the COPD group, FEV1, FEV1/FVC, and PON1 levels were significantly lower compared to the control group. Conversely, 8-OHdG, MDA, and PCO levels were significantly higher in the COPD group compared to the control group. Additionally, the levels of CRP, ESR, LDL, and total cholesterol were significantly higher in the COPD group compared to the control group. The levels of HDL, albumin, and total protein were significantly lower in the COPD group compared to the control group (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>).</p></sec><sec id="Sec12"><title>Demographic and laboratory findings</title><p id="Par41">The smoking status and the associated subgrouping of all participants are presented in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>. There was no significant difference in the duration of smoking between the COPD and control groups; however, a statistically significant difference was observed in daily smoking habits (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01). A significant difference was also noted in the disease duration between smokers and non-smokers subgroups of the COPD group (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01). FEV1 values were significantly lower in the COPD-smoker group compared to the non-smoker COPD group, but no statistical difference was found between the smoker and non-smoker control groups. Similarly, FEV1/FVC values were significantly lower in the smoker COPD group compared to the non-smoker COPD group, and were also lower in the smoker COPD group compared to the smoker control group. CRP levels were significantly higher in smoker COPD patients than in the smoker control group. ESR values were significantly higher in the smoker COPD group compared to both the smoker and non-smoker control groups. Additionally, 8-OHdG levels were significantly higher in the smoker COPD group compared to the non-smoker COPD group. Furthermore, 8-OHdG, MDA, and PCO levels were significantly higher in the smoker COPD group compared to the smoker and non-smoker control groups (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>) (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>).<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>Demographic and laboratory characteristics of the study population stratified by disease and smoking status</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="left" colspan="2" rowspan="1">Control group</th><th align="left" colspan="2" rowspan="1">COPD group</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic></th></tr><tr><th align="left" colspan="1" rowspan="1">Smoking (+) n&#8201;=&#8201;70</th><th align="left" colspan="1" rowspan="1">Smoking (&#8722;) n&#8201;=&#8201;70</th><th align="left" colspan="1" rowspan="1">Smoking (+) n&#8201;=&#8201;70</th><th align="left" colspan="1" rowspan="1">Smoking (&#8722;) n&#8201;=&#8201;71</th><th align="left" colspan="1" rowspan="1"/></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age (Year)</td><td align="left" colspan="1" rowspan="1">60.04&#8201;&#177;&#8201;5.35</td><td align="left" colspan="1" rowspan="1">60.58&#8201;&#177;&#8201;5.17</td><td align="left" colspan="1" rowspan="1">61.51&#8201;&#177;&#8201;4.95</td><td align="left" colspan="1" rowspan="1">60.82&#8201;&#177;&#8201;6.06</td><td char="." align="char" colspan="1" rowspan="1">0.699</td></tr><tr><td align="left" colspan="1" rowspan="1">Duration of cigarette smoking (Year)</td><td align="left" colspan="1" rowspan="1">32.63&#8201;&#177;&#8201;11.47</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">35.69&#8201;&#177;&#8201;10.94</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1">0.462</td></tr><tr><td align="left" colspan="1" rowspan="1">Duration of disease (Year)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">20.55&#8201;&#177;&#8201;7.43</td><td align="left" colspan="1" rowspan="1">14.72&#8201;&#177;&#8201;8.34</td><td char="." align="char" colspan="1" rowspan="1"><bold>0.01</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Number of cigarettes (Day)</td><td align="left" colspan="1" rowspan="1">21.18&#8201;&#177;&#8201;7.45</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">28.15&#8201;&#177;&#8201;10.59</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td char="." align="char" colspan="1" rowspan="1"><bold>0.01</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">FEV1 (% predicted)</td><td align="left" colspan="1" rowspan="1">101 (96&#8211;106)<sup>b***</sup></td><td align="left" colspan="1" rowspan="1">102 (96&#8211;106) <sup>c***</sup></td><td align="left" colspan="1" rowspan="1">38 (28&#8211;48)<sup>a***</sup></td><td align="left" colspan="1" rowspan="1">80 (68&#8211;88)</td><td char="." align="char" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">FEV1/FVC</td><td align="left" colspan="1" rowspan="1">82 (80&#8211;86.50)<sup>b***</sup></td><td align="left" colspan="1" rowspan="1">83 (80&#8211;87)<sup>c***</sup></td><td align="left" colspan="1" rowspan="1">49 (43&#8211;62)<sup>a***</sup></td><td align="left" colspan="1" rowspan="1">69 (65&#8211;70)</td><td char="." align="char" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">CRP (mg/L)</td><td align="left" colspan="1" rowspan="1">0.31 (0.15&#8211;0.41)<sup>b*</sup></td><td align="left" colspan="1" rowspan="1">0.31 (0.19&#8211;0.51)</td><td align="left" colspan="1" rowspan="1">0.48 (0.29&#8211;0.73)</td><td align="left" colspan="1" rowspan="1">0.36 (0.18&#8211;0.71)</td><td char="." align="char" colspan="1" rowspan="1"><bold>0.010</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">ESR (mm/h)</td><td align="left" colspan="1" rowspan="1">6 (2&#8211;10)<sup>b**</sup></td><td align="left" colspan="1" rowspan="1">9 (5&#8211;21)<sup>c**</sup></td><td align="left" colspan="1" rowspan="1">18 (14&#8211;26)</td><td align="left" colspan="1" rowspan="1">18 (8&#8211;24)</td><td char="." align="char" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Triglyceride (mg/dL)</td><td align="left" colspan="1" rowspan="1">105 (81&#8211;166)</td><td align="left" colspan="1" rowspan="1">121 (95&#8211;178)</td><td align="left" colspan="1" rowspan="1">105 (84&#8211;140)<sup>a*</sup></td><td align="left" colspan="1" rowspan="1">132 (100&#8211;187)</td><td char="." align="char" colspan="1" rowspan="1">0.053</td></tr><tr><td align="left" colspan="1" rowspan="1">LDL (mg/dL)</td><td align="left" colspan="1" rowspan="1">100 (96&#8211;107)<sup>b*</sup></td><td align="left" colspan="1" rowspan="1">127 (112&#8211;143)</td><td align="left" colspan="1" rowspan="1">111 (83&#8211;138)</td><td align="left" colspan="1" rowspan="1">139 (122&#8211;157)</td><td char="." align="char" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Total cholesterol (mg/dL)</td><td align="left" colspan="1" rowspan="1">173 (169&#8211;184)</td><td align="left" colspan="1" rowspan="1">173 (169&#8211;185)</td><td align="left" colspan="1" rowspan="1">185 (168&#8211;205) <sup>a***</sup></td><td align="left" colspan="1" rowspan="1">214 (189&#8211;246)</td><td char="." align="char" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">HDL (mg/dL)</td><td align="left" colspan="1" rowspan="1">49 (41.45&#8211;55.90)</td><td align="left" colspan="1" rowspan="1">48 (42&#8211;53)</td><td align="left" colspan="1" rowspan="1">43 (39&#8211;50)</td><td align="left" colspan="1" rowspan="1">44 (38&#8211;53)</td><td char="." align="char" colspan="1" rowspan="1">0.061</td></tr><tr><td align="left" colspan="1" rowspan="1">Albumin (g/dL)</td><td align="left" colspan="1" rowspan="1">4.11 (4.01&#8211;4.22)<sup>b***</sup></td><td align="left" colspan="1" rowspan="1">4.12 (4.05&#8211;4.22)<sup>c***</sup></td><td align="left" colspan="1" rowspan="1">3.50 (3.16&#8211;3.80)<sup>a*</sup></td><td align="left" colspan="1" rowspan="1">3.80 (3.50&#8211;3.98)</td><td char="." align="char" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Total protein (g/dL)</td><td align="left" colspan="1" rowspan="1">8.12 (7.94&#8211;8.34) <sup>b***</sup></td><td align="left" colspan="1" rowspan="1">8.14 (7.97&#8211;8.26)<sup>c***</sup></td><td align="left" colspan="1" rowspan="1">7.11 (6.71&#8211;7.50) <sup>a*</sup></td><td align="left" colspan="1" rowspan="1">7.40 (7.00&#8211;7.80)</td><td char="." align="char" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">8&#8211;OHdG (ng/mL)</td><td align="left" colspan="1" rowspan="1">3.80 (3.40&#8211;4.25)<sup>b***</sup></td><td align="left" colspan="1" rowspan="1">3.55 (3.30&#8211;3.80)<sup>c***</sup></td><td align="left" colspan="1" rowspan="1">6.00 (5.00&#8211;6.00)<sup>a***</sup></td><td align="left" colspan="1" rowspan="1">4.20 (3.70&#8211;4.60)</td><td char="." align="char" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">MDA (nmol/mL)</td><td align="left" colspan="1" rowspan="1">1.95 (1.75&#8211;2.37) <sup>b***</sup></td><td align="left" colspan="1" rowspan="1">1.96 (1.73&#8211;2.15) <sup>c***</sup></td><td align="left" colspan="1" rowspan="1">4.00 (3.00&#8211;4.00)<sup>a***</sup></td><td align="left" colspan="1" rowspan="1">2.78 (2.33&#8211;3.45)</td><td char="." align="char" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">PCO (nmol/mg.protein)</td><td align="left" colspan="1" rowspan="1">1.46 (0.93&#8211;1.64)<sup>b***</sup></td><td align="left" colspan="1" rowspan="1">0.89 (0.76&#8211;1.13)<sup>c***</sup></td><td align="left" colspan="1" rowspan="1">1.81 (1.43&#8211;2.00)<sup>a***</sup></td><td align="left" colspan="1" rowspan="1">1.35 (1.03&#8211;1.85)</td><td char="." align="char" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">PON1 (U/mL)</td><td align="left" colspan="1" rowspan="1">86.73 (80.67&#8211;91.67)<sup>b***</sup></td><td align="left" colspan="1" rowspan="1">95.32 (87.70&#8211;108.75)<sup>c***</sup></td><td align="left" colspan="1" rowspan="1">59.26 (53.08&#8211;65.00)<sup>a*</sup></td><td align="left" colspan="1" rowspan="1">65.00 (59.11&#8211;73.47)</td><td char="." align="char" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">FEV1</italic> forced expiratory volume, <italic toggle="yes">FEV1/FVC</italic> the ratio of FEV1 to forced vital capacity, <italic toggle="yes">CRP</italic> C-reactive protein, <italic toggle="yes">ESR</italic> erythrocyte sedimentation rate, <italic toggle="yes">HDL</italic> high density lipoprotein, <italic toggle="yes">LDL</italic> low density lipoprotein, <italic toggle="yes">8-OHdG</italic> 8-hydroxy-2' deoxyguanosine, <italic toggle="yes">MDA</italic> malondialdehyde, <italic toggle="yes">PCO</italic> protein carbonyl, <italic toggle="yes">PON1</italic> Paraoxonase 1</p><p>Data are presented as mean&#8201;&#177;&#8201;SD and median (25&#8211;75%)</p><p>Kruskall-Wallis test was used. Post-hoc pairwise comparisons were performed using Bonferroni correction. Values sharing different superscripts (a, b, c) differ significantly at the adjusted <italic toggle="yes">p</italic> value threshold</p><p><sup>*</sup><italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05. **<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01. ***<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001 (significance of bold)</p><p><sup>a</sup>Patient smoking (+) versus patient smoking (&#8211;)</p><p><sup>b</sup>Patient-smoking (+) versus control-smoking (+)</p><p><sup>c</sup>Patient-smoking (+) versus control-smoking (&#8211;)</p></table-wrap-foot></table-wrap><fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>Box plots of laboratory parameters by COPD and control groups. Box plots display the distribution of key laboratory parameters across four study groups: Control smokers (n&#8201;=&#8201;70), Control non-smokers (n&#8201;=&#8201;70), COPD smokers (n&#8201;=&#8201;70), and COPD non-smokers (n&#8201;=&#8201;71). The boxes represent the interquartile range (IQR), the horizontal lines inside boxes indicate the median, and the whiskers represent the range excluding outliers</p></caption><graphic id="MO1" position="float" orientation="portrait" xlink:href="12890_2025_3907_Fig1_HTML.jpg"/></fig></p></sec><sec id="Sec13"><title>Correlations related to 8-OHdG</title><p id="Par42">Correlations related to 8-OHdG in COPD patients are presented in Table&#160;<xref rid="Tab3" ref-type="table">3</xref>. A strong negative correlation was observed between 8-OHdG and both FEV1 and FEV1/FVC levels (r&#8201;=&#8201;&#8722;&#8201;0.843, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; r&#8201;=&#8201;&#8722;&#8201;0.765, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, respectively). Additionally, a moderate negative correlation was found between 8-OHdG and PON1 activity as well as total protein levels (r&#8201;=&#8201;&#8722;&#8201;0.512, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; r&#8201;=&#8201;&#8722;&#8201;0.509, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, respectively), and a weak negative correlation was noted between 8-OHdG and albumin levels (r&#8201;=&#8201;&#8722;&#8201;0.472, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). Moreover, a strong positive correlation was observed between 8-OHdG and PCO levels (r&#8201;=&#8201;0.759, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). A positive correlation was also found between smoking duration and the number of cigarettes smoked with CRP levels (r&#8201;=&#8201;0.673, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01; r&#8201;=&#8201;0.596, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01, respectively) (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table&#160;3</label><caption><p>Spearman correlation analysis between 8-OHdG and other parameters in COPD patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="left" colspan="2" rowspan="1">8-OHdG</th></tr><tr><th align="left" colspan="1" rowspan="1">r</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic></th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">FEV1 (% predicted)</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;0.843</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">FEV1/FVC</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;0.765</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">CRP (mg/L)</td><td align="left" colspan="1" rowspan="1">0.225</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">ESR (mm/h)</td><td align="left" colspan="1" rowspan="1">0.306</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">HDL (mg/dL)</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;0.148</td><td char="." align="char" colspan="1" rowspan="1">0.041</td></tr><tr><td align="left" colspan="1" rowspan="1">Albumin (g/dL)</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;0.472</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Total Protein (g/dL)</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;0.509</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">MDA (ng/mL)</td><td align="left" colspan="1" rowspan="1">0.518</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">PCO (nmol/mg.protein)</td><td align="left" colspan="1" rowspan="1">0.759</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">PON1 (U/mL)</td><td align="left" colspan="1" rowspan="1">&#8722;&#8201;0.512</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">8-OHdG</italic> 8-hydroxy-2&#8242; deoxyguanosine, <italic toggle="yes">FEV1</italic> forced expiratory volume, <italic toggle="yes">FEV1/FVC</italic> the ratio of FEV1 to forced vital capacity, <italic toggle="yes">CRP</italic> C-reactive protein, <italic toggle="yes">ESR</italic> erythrocyte sedimentation rate, <italic toggle="yes">HDL</italic> high density lipoprotein, <italic toggle="yes">MDA</italic> malon- dialdehyde, <italic toggle="yes">PCO</italic> protein carbonyl, <italic toggle="yes">PON1</italic> paraoxonase1</p></table-wrap-foot></table-wrap></p><p id="Par43">We also found a positive relationship between 8-OHdG and CRP, ESR, MDA and PCO (r&#8201;=&#8201;0.225, <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.001; r&#8201;=&#8201;0.306, <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.001; r&#8201;=&#8201;0.518, <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.001; r&#8201;=&#8201;0.759, <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.001, respectively) and a negative relationship between 8-OHdG and FEV1, FEV1/FVC, HDL, albumin, total protein and PON1 (r&#8201;=&#8201;&#8722;&#8201;0.843, <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.001; r&#8201;=&#8201;&#8722;&#8201;0.765, <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.001; r&#8201;=&#8201;&#8722;&#8201;0.162, <italic toggle="yes">p</italic>&#8201;=&#8201;0.025; r&#8201;=&#8201;&#8722;&#8201;0.148, <italic toggle="yes">p</italic>&#8201;=&#8201;0.041; r&#8201;=&#8201;&#8722;&#8201;0.472, <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.001; r&#8201;=&#8201;&#8722;&#8201;0.509, <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.001; r&#8201;=&#8201;&#8722;&#8201;0.512, <italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.001, respectively) (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>).</p></sec><sec id="Sec14"><title>Multinomial logistic regression analysis</title><p id="Par44">Multivariate analysis revealed that 8-OHdG levels were significantly lower in all non-COPD groups, highlighting its potential as a discriminative biomarker for identifying individuals with smoking-related COPD. PON1 activity was found to be significantly higher in both control groups, suggesting its possible protective antioxidant role in individuals without COPD. PCO levels showed a positive association with both non-smoking COPD group and smoking control group, indicating that protein oxidation may occur in the context of COPD or smoking independently. In contrast, MDA levels did not exhibit a significant independent association with group classification in the multivariate model (Table&#160;<xref rid="Tab4" ref-type="table">4</xref>).<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table&#160;4</label><caption><p>Multivariate logistic regression results</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Association with smoking (&#8722;) COPD group</th><th align="left" colspan="1" rowspan="1">Association with smoking (&#8211;) control group</th><th align="left" colspan="1" rowspan="1">Association with smoking (+) control group</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">8-OHdG</td><td align="left" colspan="1" rowspan="1">&#8595; (<italic toggle="yes">p</italic>&#8201;=&#8201;0.003)</td><td align="left" colspan="1" rowspan="1">&#8595; (<italic toggle="yes">p</italic>&#8201;=&#8201;0.002)</td><td align="left" colspan="1" rowspan="1">&#8595; (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001)</td></tr><tr><td align="left" colspan="1" rowspan="1">PON1</td><td align="left" colspan="1" rowspan="1">ns</td><td align="left" colspan="1" rowspan="1">&#8593; (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001)</td><td align="left" colspan="1" rowspan="1">&#8593; (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001)</td></tr><tr><td align="left" colspan="1" rowspan="1">PCO</td><td align="left" colspan="1" rowspan="1">&#8593; (<italic toggle="yes">p</italic>&#8201;=&#8201;0.008)</td><td align="left" colspan="1" rowspan="1">ns</td><td align="left" colspan="1" rowspan="1">&#8593; (<italic toggle="yes">p</italic>&#8201;=&#8201;0.023)</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec15"><title>ROC curve analysis</title><p id="Par45">When the cut-off value obtained from the ROC analysis of smoking COPD patients was taken as 5, the sensitivity of 8-OHdG was found to be 100%, the specificity was 97.2%, and the positive predictive value was 97.2%. (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>, Table&#160;<xref rid="Tab4" ref-type="table">4</xref>). The cut off for MDA was higher than 3, with 90.0% in sensitivity and 59.2% in specificity. The cut off for PCO was higher than 1.15, with 95.7% in sensitivity and 33.8% in specificity. (For higher than 1.3, 87.1% in sensitivity and 43.7% in specificity; for higher than 1.36, 80.0% in sensitivity and 53.5% in specificity). The cut-off for FEV1 was lower than 53.5 with 98.6% in sensitivity and 100% in specificity. The cut-off for FEV1/FVC was lower than 67.5, with 92.9% in sensitivity and 71.8% in specificity. The cut-off for PON1 was lower than 65, with 72.9% in sensitivity and 52.1% in specificity (Table&#160;<xref rid="Tab5" ref-type="table">5</xref>).<fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>ROC curve for smoker patients with COPD</p></caption><graphic id="MO2" position="float" orientation="portrait" xlink:href="12890_2025_3907_Fig2_HTML.jpg"/></fig><table-wrap id="Tab5" position="float" orientation="portrait"><label>Table&#160;5</label><caption><p>ROC curve analysis for smoker patients with COPD</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Variables</th><th align="left" colspan="1" rowspan="1">AUC (95% CI)</th><th align="left" colspan="1" rowspan="1">Cut-off</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic></th><th align="left" colspan="1" rowspan="1">Sensitivity (%)</th><th align="left" colspan="1" rowspan="1">Specificity (%)</th><th align="left" colspan="1" rowspan="1">PPV (%95 CI)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">8-OHdG</td><td align="left" colspan="1" rowspan="1">0.987 (0.969&#8211;1.000)</td><td align="left" colspan="1" rowspan="1">5<sup>a</sup></td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">100</td><td align="left" colspan="1" rowspan="1">97.2</td><td align="left" colspan="1" rowspan="1">92.6 (85.4&#8211;96.3)</td></tr><tr><td align="left" colspan="1" rowspan="1">MDA</td><td align="left" colspan="1" rowspan="1">0.756 (0.675&#8211;0.836)</td><td align="left" colspan="1" rowspan="1">3<sup>a</sup></td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">90.0</td><td align="left" colspan="1" rowspan="1">59.2</td><td align="left" colspan="1" rowspan="1">68.5 (59.1&#8211;77.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">PCO</td><td align="left" colspan="1" rowspan="1">0.704 (0.619&#8211;0.790)</td><td align="left" colspan="1" rowspan="1">1.30<sup>a</sup></td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">87.1</td><td align="left" colspan="1" rowspan="1">43.7</td><td align="left" colspan="1" rowspan="1">60.4 (50.2&#8211;69.1)</td></tr><tr><td align="left" colspan="1" rowspan="1">FEV1</td><td align="left" colspan="1" rowspan="1">0.999 (0.995&#8211;1.000)</td><td align="left" colspan="1" rowspan="1">53.5<sup>b</sup></td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">98.6</td><td align="left" colspan="1" rowspan="1">100</td><td align="left" colspan="1" rowspan="1">100 (94.7&#8211;100)</td></tr><tr><td align="left" colspan="1" rowspan="1">FEV1/FVC</td><td align="left" colspan="1" rowspan="1">0.887 (0.833&#8211;0.941)</td><td align="left" colspan="1" rowspan="1">67.5<sup>b</sup></td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">92.9</td><td align="left" colspan="1" rowspan="1">71.8</td><td align="left" colspan="1" rowspan="1">76.5 (67.4&#8211;85)</td></tr><tr><td align="left" colspan="1" rowspan="1">PON1</td><td align="left" colspan="1" rowspan="1">0.684 (0.597&#8211;0.771)</td><td align="left" colspan="1" rowspan="1">65<sup>b</sup></td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">72.9</td><td align="left" colspan="1" rowspan="1">52.1</td><td align="left" colspan="1" rowspan="1">60.0 (50&#8211;70.5)</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">8-OHdG</italic> 8-hydroxy-2&#8242; deoxyguanosine, <italic toggle="yes">MDA</italic> malondialdehyde, <italic toggle="yes">PCO</italic> protein carbonyl, <italic toggle="yes">FEV1</italic> forced expiratory volume, <italic toggle="yes">FEV1/FVC</italic> the ratio of FEV1 to forced vital capacity, <italic toggle="yes">PON1</italic> paraoxonase 1, <italic toggle="yes">PPV</italic> positive predictive value, <italic toggle="yes">CI</italic> confidence intervals</p><p><sup>a</sup>If greater than cut-off</p><p><sup>b</sup>If lower than cut-off</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec16"><title>Discussion</title><p id="Par46">In this study, we investigated the oxidative stress profile and inflammatory markers in patients with COPD, focusing on the impact of smoking. Our findings demonstrate significant alterations in both oxidative damage biomarkers and antioxidant enzyme activities in COPD patients compared to healthy controls. Oxidative stress markers such as 8-OHdG, MDA, and PCO are significantly elevated in COPD patients, especially smokers, while antioxidant enzyme PON1 activity is reduced. These changes correlate with impaired lung function (lower FEV1 and FEV1/FVC) and increased systemic inflammation (CRP and ESR). The strong negative correlation between 8-OHdG and lung function, along with its high diagnostic accuracy, suggests that 8-OHdG is a promising biomarker for COPD severity. Overall, our findings highlight the critical role of smoking-induced oxidative damage and antioxidant depletion in COPD pathogenesis and progression. As this study was designed as a cross-sectional observational analysis, it does not permit causal inference, although it enables the identification of associations between variables.</p><p id="Par47">COPD is a complex inflammatory condition primarily affecting the lungs but with systemic consequences [<xref ref-type="bibr" rid="CR22">22</xref>]. Oxidative stress plays a central role in COPD pathogenesis by disrupting the balance between oxidants and antioxidants [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. In this study, smokers with COPD exhibited elevated circulating levels of oxidative stress markers (8-OHdG, MDA, and PCO) while antioxidant enzyme PON1 activity was decreased. These findings align with previous reports linking increased oxidative damage to impaired lung function and systemic inflammation in COPD patients [<xref ref-type="bibr" rid="CR3">3</xref>&#8211;<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par48">Previous studies have confirmed the strong association between smoking and COPD [<xref ref-type="bibr" rid="CR23">23</xref>]. Cigarette smoke generates reactive oxygen species (ROS) that damage lipids, proteins, and DNA, thereby stimulating inflammation through the activation of immune cells [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. In this study, 8-OHdG, a well-established marker of oxidative DNA damage, was significantly elevated in COPD patients, especially among smokers, with ROC analysis showing high sensitivity (100%) and specificity (97.2%). Positive correlations between 8-OHdG and inflammatory markers (CRP, ESR, MDA, PCO) and negative correlations with lung function parameters (FEV1, FEV1/FVC) and antioxidants (PON1) suggest that smoking-induced oxidative stress leads to DNA damage in COPD. These findings support that serum 8-OHdG may have potential as a supportive biomarker, pending validation in longitudinal studies and multivariate-adjusted analyses in COPD [<xref ref-type="bibr" rid="CR26">26</xref>&#8211;<xref ref-type="bibr" rid="CR33">33</xref>]. A weak negative correlation between 8-OHdG and albumin and total protein was also observed.</p><p id="Par49">Lipids are major targets of oxidative stress, with malondialdehyde (MDA), a product of polyunsaturated fatty acid peroxidation, widely used as an oxidative stress biomarker. Numerous studies have demonstrated increased MDA levels and disturbed oxidant/antioxidant balance in COPD patients [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. Nadeem et al. [<xref ref-type="bibr" rid="CR36">36</xref>] and Joppa et al. [<xref ref-type="bibr" rid="CR37">37</xref>] reported elevated plasma and serum MDA in COPD compared to healthy controls. Kluchova et al. [<xref ref-type="bibr" rid="CR38">38</xref>] found higher MDA and lower erythrocyte GPX activity in severe versus moderate COPD, with MDA negatively correlating with FEV1. MDA levels also rise during COPD exacerbations and normalize after treatment, highlighting its potential as a marker for disease activity [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. Animal studies further confirm increased MDA and reduced antioxidant enzymes in smoke-exposed lung tissue [<xref ref-type="bibr" rid="CR41">41</xref>]. In the current study, MDA levels were significantly elevated primarily in the smoker COPD patient group compared to both smoker and non-smoker control groups, emphasizing the role of lipid peroxidation in COPD pathogenesis and the vulnerability of lung tissue to oxidative damage.</p><p id="Par50">ROS, especially hydroxyl radicals, induce oxidative modifications in intracellular proteins, resulting in oxidative damage [<xref ref-type="bibr" rid="CR42">42</xref>]. PCO is a widely used marker of protein oxidation and oxidative stress in various diseases. In this study, PCO levels were significantly elevated in the smoker COPD patient group compared to both smoker and non-smoker control groups, with the lowest levels observed in the non-smoker control group. With a cut-off value&#8201;&gt;&#8201;1.15 and 95.7% sensitivity, PCO may be a useful indicator of oxidative damage; however, further longitudinal and adjusted studies are warranted to confirm its utility as a biomarker [<xref ref-type="bibr" rid="CR14">14</xref>]. Yessica et al. [<xref ref-type="bibr" rid="CR43">43</xref>] demonstrated that COPD progression is associated with increased PCO and CRP levels, reflecting chronic inflammation. Nadeem et al. [<xref ref-type="bibr" rid="CR36">36</xref>] similarly reported elevated plasma PCO in mostly smoking COPD patients. However, some studies report inconsistent associations between plasma PCO and lung function or disease severity [<xref ref-type="bibr" rid="CR44">44</xref>], while others show elevated protein oxidation markers in exhaled breath condensate of COPD patients [<xref ref-type="bibr" rid="CR45">45</xref>]. Despite discrepancies, smoking promotes PCO formation, and increased ROS contributes to cellular and DNA damage in COPD pathogenesis.</p><p id="Par51">PON1 is an antioxidant enzyme associated with high-density lipoprotein (HDL) and prevents the oxidation of low-density lipoprotein (LDL). Smoking has been shown to inhibit PON1 activity by modifying its free thiol groups [<xref ref-type="bibr" rid="CR16">16</xref>]. In our study, PON1 activity was significantly lower in smokers with COPD compared to non-smokers and the control group. A negative correlation was observed between 8-OHdG and FEV1, FEV1/FVC, HDL, and PON1, though no significant association was found between LDL, HDL, and PON1. Consistent with our findings, I&#351;&#305;k et al. [<xref ref-type="bibr" rid="CR46">46</xref>] and meta-analyses [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>] reported reduced PON1 activity in COPD patients and smokers, indicating impaired antioxidant defense. Rumora et al. [<xref ref-type="bibr" rid="CR48">48</xref>] linked decreased PON1 activity to altered serum HDL levels in COPD patients. They have reported that PON1 and arylesterase activities significantly decreased in COPD patients compared to the control group. However, Sarioglu et al. [<xref ref-type="bibr" rid="CR18">18</xref>] found that PON1 was increased, but arylesterase activity was decreased in COPD patients. These conflicting findings might be explained by differences in the severity of disease among the patient groups studied [<xref ref-type="bibr" rid="CR49">49</xref>]. In our study, all the COPD patients were in their stable stage in the past three months. Oxidative stress contributes to lung injury and inflammation by disrupting redox homeostasis. Our results support that smoking impairs PON1 activity, even in healthy individuals, promoting elevated ROS and oxidative damage in lung tissue. Although GOLD stage data were collected, we did not perform a detailed subgroup analysis due to limited sample sizes. Initial observations suggest that oxidative stress markers may be higher in patients with more advanced COPD. This should be explored further in future studies with larger cohorts.</p><p id="Par52">A meta-analysis of 14 studies reported that systemic inflammation persists in COPD patients, including non-smokers, indicating that inflammation may continue despite smoking cessation [<xref ref-type="bibr" rid="CR49">49</xref>]. Consistently, our study found a positive correlation between smoking duration, cigarette consumption, and CRP levels. CRP was significantly elevated in COPD patients with increased smoking exposure and longer disease duration, supporting the presence of ongoing systemic inflammation in COPD. Our findings confirm that CRP levels are significantly elevated in COPD patients with greater smoking exposure and longer disease duration, thereby supporting the presence of persistent systemic inflammation in COPD.</p><sec id="Sec17"><title>Limitations</title><p id="Par53">The most important limitations of our study include the lack of evaluation of alpha-1 antitrypsin (AAT) enzyme levels, which are known to influence COPD pathogenesis, and the relatively small size of the control group. Additionally, our study was conducted at a single center, which may limit the generalizability of the findings to broader populations. We also did not assess other potentially influential factors such as genetic predispositions beyond AAT, or lifestyle factors including diet and environmental exposures, which could affect oxidative stress and antioxidant capacity. One limitation of this study is that the COPD-smoker group included both current and former smokers, but no subgroup analysis was performed to compare oxidative stress biomarker levels between these two subgroups. Our future studies will investigate whether quitting smoking leads to measurable improvements in oxidative stress markers. Future studies involving larger, multi-center cohorts with comprehensive laboratory, genetic, and lifestyle evaluations are warranted to better understand these complex interactions and to strengthen the clinical relevance of these biomarkers in COPD.</p></sec></sec><sec id="Sec18"><title>Conclusions</title><p id="Par54">Our findings suggest that COPD is associated with oxidative stress and impaired antioxidant defenses, particularly in smokers. Elevated levels of oxidative stress markers (8-OHdG, MDA, and PCO) and reduced PON1 activity observed in this study reflect a disruption in redox homeostasis, which may contribute to cellular and DNA damage in COPD patients. Notably, 8-OHdG levels were negatively correlated with lung function parameters and antioxidant enzyme activity, suggesting its potential utility&#8212;alongside PON1 as a supportive biomarker for disease monitoring. However, due to the cross-sectional design and lack of multivariate adjustment, causal relationships cannot be established. Further longitudinal and mechanistic studies are warranted to validate these findings and explore the clinical relevance of these biomarkers in the progression and management of COPD. Emphasis on smoking cessation and antioxidant-based therapeutic strategies remain essential in addressing the underlying oxidative burden in COPD. However, these results should be interpreted within the context of the study&#8217;s limitations, and future studies are necessary to explore their prognostic or therapeutic relevance.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>8-OHdG</term><def><p id="Par5">8-Hydroxy-2&#8242; deoxyguanosine</p></def></def-item><def-item><term>ACOS</term><def><p id="Par6">Asthma-COPD overlap syndrome</p></def></def-item><def-item><term>AECOPD</term><def><p id="Par7">Acute exacerbation of chronic obstructive pulmonary disease</p></def></def-item><def-item><term>ARE</term><def><p id="Par8">Arylesterase</p></def></def-item><def-item><term>COPD</term><def><p id="Par9">Chronic obstructive pulmonary disease</p></def></def-item><def-item><term>CRP</term><def><p id="Par10">C-reactive protein</p></def></def-item><def-item><term>FEV</term><def><p id="Par11">Forced expiratory volume</p></def></def-item><def-item><term>FVC</term><def><p id="Par12">Forced vital capacity</p></def></def-item><def-item><term>H2O2</term><def><p id="Par13">Hydrogen peroxide</p></def></def-item><def-item><term>HOCl</term><def><p id="Par14">Hypochlorous acid</p></def></def-item><def-item><term>LDL</term><def><p id="Par15">Low-density lipoprotein</p></def></def-item><def-item><term>LPO</term><def><p id="Par16">Lipid peroxidation</p></def></def-item><def-item><term>MDA</term><def><p id="Par17">Malondialdehyde</p></def></def-item><def-item><term>PCO</term><def><p id="Par18">Protein carbonyl</p></def></def-item><def-item><term>PFT</term><def><p id="Par19">Pulmonary function tests</p></def></def-item><def-item><term>PON</term><def><p id="Par20">Paraoxonase</p></def></def-item><def-item><term>RNS</term><def><p id="Par21">Reactive nitrogen species</p></def></def-item><def-item><term>ROC</term><def><p id="Par22">Receiver operating characteristics</p></def></def-item><def-item><term>ROS</term><def><p id="Par23">Reactive oxygen species</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>None</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Conceptualization: O.E.J., P.U., S.D., H.U.; statistical analysis: S.D. and H.U.; investigation: O.E.J., P.U., S.D., A.K.F., H.U.; methodology: O.E.J., P.U., S.D., A.K.F., H.U.; project administration: O.E.J., P.U., S.D., A.K.F., and H.U.; supervision: O.E.J., P.U., and H.U.; writing original draft: O.E.J., P.U., S.D., A.K.F., H.U.; writing review and editing: A.K.F. and H.U. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data underlying this article are available in the article. If needed, please contact the corresponding author. The email address is huzun59@hotmail.com.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par55">This study received approval from the Ethics Committee of Istanbul Atlas University Medical Faculty (protocol number: E-22686390-050.01. 04-8486/2021) and written informed consent was obtained from all participants. The study was conducted in compliance with the Declaration of Helsinki.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par56">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par57">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halpin</surname><given-names>DMG</given-names></name><name name-style="western"><surname>Criner</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Papi</surname><given-names>A</given-names></name><name name-style="western"><surname>Singh</surname><given-names>D</given-names></name><name name-style="western"><surname>Anzueto</surname><given-names>A</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>FJ</given-names></name><etal/></person-group><article-title>Global initiative for diagnosis, management, and prevention of chronic obstructive lung disease. The 2020 GOLD science committee report on COVID-19 and chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>2021</year><volume>203</volume><issue>1</issue><fpage>24</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1164/rccm.202009-3533SO</pub-id><pub-id pub-id-type="pmid">33146552</pub-id><pub-id pub-id-type="pmcid">PMC7781116</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Halpin DMG, Criner GJ, Papi A, Singh D, Anzueto A, Martinez FJ, et al. Global initiative for diagnosis, management, and prevention of chronic obstructive lung disease. The 2020 GOLD science committee report on COVID-19 and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2021;203(1):24&#8211;36. 10.1164/rccm.202009-3533SO.<pub-id pub-id-type="pmid">33146552</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.202009-3533SO</pub-id><pub-id pub-id-type="pmcid">PMC7781116</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Global strategy for the diagnosis, management and prevention of COPD, Global initiative for chronic obstructive lung disease (GOLD); 2020. Accessed 22 May 2025. <ext-link ext-link-type="uri" xlink:href="http://goldcopd.org">http://goldcopd.org</ext-link></mixed-citation></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reyfman</surname><given-names>PA</given-names></name><name name-style="western"><surname>Washko</surname><given-names>GR</given-names></name><name name-style="western"><surname>Dransfield</surname><given-names>MT</given-names></name><name name-style="western"><surname>Spira</surname><given-names>A</given-names></name><name name-style="western"><surname>Han</surname><given-names>MK</given-names></name><name name-style="western"><surname>Kalhan</surname><given-names>R</given-names></name></person-group><article-title>Defining impaired respiratory health. A paradigm shift for pulmonary medicine</article-title><source>Am J Respir Crit Care Med</source><year>2018</year><volume>198</volume><fpage>440</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1164/rccm.201801-0120PP</pub-id><pub-id pub-id-type="pmid">29624449</pub-id><pub-id pub-id-type="pmcid">PMC6118019</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Reyfman PA, Washko GR, Dransfield MT, Spira A, Han MK, Kalhan R. Defining impaired respiratory health. A paradigm shift for pulmonary medicine. Am J Respir Crit Care Med. 2018;198:440&#8211;6. 10.1164/rccm.201801-0120PP.<pub-id pub-id-type="pmid">29624449</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.201801-0120PP</pub-id><pub-id pub-id-type="pmcid">PMC6118019</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raha</surname><given-names>S</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>BH</given-names></name></person-group><article-title>Mitochondria, oxygen free radicals, disease and ageing</article-title><source>Trends Biochem Sci</source><year>2000</year><volume>25</volume><fpage>502</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1016/s0968-0004(00)01674-1</pub-id><pub-id pub-id-type="pmid">11050436</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Raha S, Robinson BH. Mitochondria, oxygen free radicals, disease and ageing. Trends Biochem Sci. 2000;25:502&#8211;8. 10.1016/s0968-0004(00)01674-1.<pub-id pub-id-type="pmid">11050436</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0968-0004(00)01674-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cochrane</surname><given-names>CG</given-names></name></person-group><article-title>Cellular injury by oxidants</article-title><source>Am J Med</source><year>1991</year><volume>91</volume><issue>3C</issue><fpage>23S</fpage><lpage>30S</lpage><pub-id pub-id-type="doi">10.1016/0002-9343(91)90280-b</pub-id><pub-id pub-id-type="pmid">1928208</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Cochrane CG. Cellular injury by oxidants. Am J Med. 1991;91(3C):23S-30S. 10.1016/0002-9343(91)90280-b.<pub-id pub-id-type="pmid">1928208</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0002-9343(91)90280-b</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barnes</surname><given-names>PJ</given-names></name></person-group><article-title>Oxidative stress in chronic obstructive pulmonary disease</article-title><source>Antioxidants</source><year>2022</year><volume>11</volume><fpage>965</fpage><pub-id pub-id-type="doi">10.3390/antiox11050965</pub-id><pub-id pub-id-type="pmid">35624831</pub-id><pub-id pub-id-type="pmcid">PMC9138026</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Barnes PJ. Oxidative stress in chronic obstructive pulmonary disease. Antioxidants. 2022;11:965. 10.3390/antiox11050965.<pub-id pub-id-type="pmid">35624831</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antiox11050965</pub-id><pub-id pub-id-type="pmcid">PMC9138026</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dizdaroglu</surname><given-names>M</given-names></name></person-group><article-title>Facts about the artifacts in the measurement of oxidative DNA base damage by gas chromatography-mass spectrometry</article-title><source>Free Radic Res</source><year>1998</year><volume>29</volume><issue>6</issue><fpage>551</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1080/10715769800300591</pub-id><pub-id pub-id-type="pmid">10098459</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Dizdaroglu M. Facts about the artifacts in the measurement of oxidative DNA base damage by gas chromatography-mass spectrometry. Free Radic Res. 1998;29(6):551&#8211;63. 10.1080/10715769800300591.<pub-id pub-id-type="pmid">10098459</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10715769800300591</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Martinis</surname><given-names>BS</given-names></name><name name-style="western"><surname>de Lourdes Pires Bianchi</surname><given-names>M</given-names></name></person-group><article-title>Methodology for urinary 8-hydroxy-2&#8242;-deoxyguanosine analysis by HPLC with electrochemical detection</article-title><source>Pharmacol Res</source><year>2002</year><volume>46</volume><issue>2</issue><fpage>129</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/s1043-6618(02)00080-4</pub-id><pub-id pub-id-type="pmid">12220951</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">De Martinis BS, de Lourdes Pires Bianchi M. Methodology for urinary 8-hydroxy-2&#8242;-deoxyguanosine analysis by HPLC with electrochemical detection. Pharmacol Res. 2002;46(2):129&#8211;31. 10.1016/s1043-6618(02)00080-4.<pub-id pub-id-type="pmid">12220951</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1043-6618(02)00080-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>HI</given-names></name><name name-style="western"><surname>Liou</surname><given-names>SH</given-names></name><name name-style="western"><surname>Ho</surname><given-names>SF</given-names></name><name name-style="western"><surname>Wu</surname><given-names>KY</given-names></name><name name-style="western"><surname>Sun</surname><given-names>CW</given-names></name><name name-style="western"><surname>Chen</surname><given-names>MF</given-names></name><etal/></person-group><article-title>Oxidative DNA damage estimated by plasma 8-hydroxydeoxyguanosine (8-OHdG): influence of 4, 4&#8242;-methylenebis (2-chloroaniline) exposure and smoking</article-title><source>J Occup Health</source><year>2007</year><volume>49</volume><issue>5</issue><fpage>389</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.3906/sag-1807-106</pub-id><pub-id pub-id-type="pmid">17951971</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Chen HI, Liou SH, Ho SF, Wu KY, Sun CW, Chen MF, et al. Oxidative DNA damage estimated by plasma 8-hydroxydeoxyguanosine (8-OHdG): influence of 4, 4&#8242;-methylenebis (2-chloroaniline) exposure and smoking. J Occup Health. 2007;49(5):389&#8211;98. 10.3906/sag-1807-106.<pub-id pub-id-type="pmid">17951971</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1539/joh.49.389</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Esterbauer</surname><given-names>H</given-names></name><name name-style="western"><surname>Cheeseman</surname><given-names>KH</given-names></name></person-group><article-title>Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal</article-title><source>Methods Enzymol</source><year>1990</year><volume>186</volume><fpage>407</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1016/0076-6879(90)86134-h</pub-id><pub-id pub-id-type="pmid">2233308</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Esterbauer H, Cheeseman KH. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol. 1990;186:407&#8211;21. 10.1016/0076-6879(90)86134-h.<pub-id pub-id-type="pmid">2233308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0076-6879(90)86134-h</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pryor</surname><given-names>WA</given-names></name></person-group><article-title>On the detection of lipid hydroperoxides in biological samples</article-title><source>Free Radic Biol Med</source><year>1989</year><volume>7</volume><fpage>177</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1016/0891-5849(89)90010-5</pub-id><pub-id pub-id-type="pmid">2806941</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Pryor WA. On the detection of lipid hydroperoxides in biological samples. Free Radic Biol Med. 1989;7:177&#8211;8. 10.1016/0891-5849(89)90010-5.<pub-id pub-id-type="pmid">2806941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0891-5849(89)90010-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prokai</surname><given-names>L</given-names></name><name name-style="western"><surname>Yan</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Vera-Serrano</surname><given-names>JL</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>SM</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Forster</surname><given-names>MJ</given-names></name></person-group><article-title>Mass spectrometry-based survey of age-associated protein carbonylation in rat brain mitochondria</article-title><source>J Mass Spectrom</source><year>2007</year><volume>42</volume><issue>12</issue><fpage>1583</fpage><lpage>1589</lpage><pub-id pub-id-type="doi">10.1002/jms.1345</pub-id><pub-id pub-id-type="pmid">18085547</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Prokai L, Yan LJ, Vera-Serrano JL, Stevens SM Jr, Forster MJ. Mass spectrometry-based survey of age-associated protein carbonylation in rat brain mitochondria. J Mass Spectrom. 2007;42(12):1583&#8211;9. 10.1002/jms.1345.<pub-id pub-id-type="pmid">18085547</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jms.1345</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rao</surname><given-names>RS</given-names></name><name name-style="western"><surname>Moller</surname><given-names>IM</given-names></name></person-group><article-title>Pattern of occurrence and occupancy of carbonylation sites in proteins</article-title><source>Proteomics</source><year>2011</year><volume>11</volume><issue>21</issue><fpage>4166</fpage><lpage>4173</lpage><pub-id pub-id-type="doi">10.1002/pmic.201100223</pub-id><pub-id pub-id-type="pmid">21919202</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Rao RS, Moller IM. Pattern of occurrence and occupancy of carbonylation sites in proteins. Proteomics. 2011;11(21):4166&#8211;73. 10.1002/pmic.201100223.<pub-id pub-id-type="pmid">21919202</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pmic.201100223</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dalle-Donne</surname><given-names>I</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>R</given-names></name><name name-style="western"><surname>Giustarini</surname><given-names>D</given-names></name><name name-style="western"><surname>Mirzani</surname><given-names>A</given-names></name><name name-style="western"><surname>Colombo</surname><given-names>R</given-names></name></person-group><article-title>Protein carbonyl groups as biomarkers of oxidative stress</article-title><source>Clin Chim Acta</source><year>2003</year><volume>329</volume><issue>1&#8211;2</issue><fpage>23</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/S0009-8981(03)00003-2</pub-id><pub-id pub-id-type="pmid">12589963</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Dalle-Donne I, Rossi R, Giustarini D, Mirzani A, Colombo R. Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta. 2003;329(1&#8211;2):23&#8211;38. 10.1016/S0009-8981(03)00003-2.<pub-id pub-id-type="pmid">12589963</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0009-8981(03)00003-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mackness</surname><given-names>MI</given-names></name><name name-style="western"><surname>Arrol</surname><given-names>S</given-names></name><name name-style="western"><surname>Abbott</surname><given-names>C</given-names></name><name name-style="western"><surname>Durrington</surname><given-names>PN</given-names></name></person-group><article-title>Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase</article-title><source>Atherosclerosis</source><year>1993</year><volume>104</volume><issue>1&#8211;2</issue><fpage>129</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1016/0021-9150(93)90183-u</pub-id><pub-id pub-id-type="pmid">8141836</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 1993;104(1&#8211;2):129&#8211;35. 10.1016/0021-9150(93)90183-u.<pub-id pub-id-type="pmid">8141836</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0021-9150(93)90183-u</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aviram</surname><given-names>M</given-names></name><name name-style="western"><surname>Rosenblat</surname><given-names>M</given-names></name><name name-style="western"><surname>Billecke</surname><given-names>S</given-names></name><name name-style="western"><surname>Erogul</surname><given-names>J</given-names></name><name name-style="western"><surname>Sorenson</surname><given-names>R</given-names></name><name name-style="western"><surname>Bisgaier</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants</article-title><source>Free Radic Biol Med</source><year>1999</year><volume>26</volume><issue>7&#8211;8</issue><fpage>892</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1016/s0891-5849(98)00272-x</pub-id><pub-id pub-id-type="pmid">10232833</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med. 1999;26(7&#8211;8):892&#8211;904. 10.1016/s0891-5849(98)00272-x.<pub-id pub-id-type="pmid">10232833</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0891-5849(98)00272-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Camps</surname><given-names>J</given-names></name><name name-style="western"><surname>Marsillach</surname><given-names>J</given-names></name><name name-style="western"><surname>Joven</surname><given-names>J</given-names></name></person-group><article-title>The paraoxonases: role in human diseases and methodological difficulties in measurement</article-title><source>Crit Rev Clin Lab Sci</source><year>2009</year><volume>46</volume><issue>2</issue><fpage>83</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1080/10408360802610878</pub-id><pub-id pub-id-type="pmid">19255916</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Camps J, Marsillach J, Joven J. The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci. 2009;46(2):83&#8211;106. 10.1080/10408360802610878.<pub-id pub-id-type="pmid">19255916</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10408360802610878</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarioglu</surname><given-names>N</given-names></name><name name-style="western"><surname>Bilen</surname><given-names>C</given-names></name><name name-style="western"><surname>Cevik</surname><given-names>C</given-names></name><name name-style="western"><surname>Gencer</surname><given-names>N</given-names></name></person-group><article-title>Paraoxonase activity and phenotype distribution in patients with chronic obstructive pulmonary disease</article-title><source>Eurasian J Med</source><year>2020</year><volume>52</volume><issue>2</issue><fpage>161</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.5152/eurasianjmed.2019.19122</pub-id><pub-id pub-id-type="pmid">32612424</pub-id><pub-id pub-id-type="pmcid">PMC7311125</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Sarioglu N, Bilen C, Cevik C, Gencer N. Paraoxonase activity and phenotype distribution in patients with chronic obstructive pulmonary disease. Eurasian J Med. 2020;52(2):161&#8211;5. 10.5152/eurasianjmed.2019.19122.<pub-id pub-id-type="pmid">32612424</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5152/eurasianjmed.2019.19122</pub-id><pub-id pub-id-type="pmcid">PMC7311125</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buege</surname><given-names>JA</given-names></name><name name-style="western"><surname>Aust</surname><given-names>SD</given-names></name></person-group><article-title>Microsomal lipid peroxidation</article-title><source>Methods Enzymol</source><year>1978</year><volume>52</volume><fpage>302</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1016/s0076-6879(78)52032-6</pub-id><pub-id pub-id-type="pmid">672633</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol. 1978;52:302&#8211;10. 10.1016/s0076-6879(78)52032-6.<pub-id pub-id-type="pmid">672633</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0076-6879(78)52032-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reznick</surname><given-names>AZ</given-names></name><name name-style="western"><surname>Packer</surname><given-names>L</given-names></name></person-group><article-title>Oxidative damage to proteins: spectrophotometric method for carbonyl assay</article-title><source>Methods Enzymol</source><year>1994</year><volume>233</volume><fpage>357</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1016/s0076-6879(94)33041-7</pub-id><pub-id pub-id-type="pmid">8015470</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Reznick AZ, Packer L. Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Methods Enzymol. 1994;233:357&#8211;63. 10.1016/s0076-6879(94)33041-7.<pub-id pub-id-type="pmid">8015470</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0076-6879(94)33041-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hasselwander</surname><given-names>O</given-names></name><name name-style="western"><surname>Savage</surname><given-names>DA</given-names></name><name name-style="western"><surname>McMaster</surname><given-names>D</given-names></name><name name-style="western"><surname>Loughrey</surname><given-names>CM</given-names></name><name name-style="western"><surname>McNamee</surname><given-names>PT</given-names></name><name name-style="western"><surname>Middleton</surname><given-names>D</given-names></name><etal/></person-group><article-title>Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients</article-title><source>Kidney Int</source><year>1999</year><volume>56</volume><issue>1</issue><fpage>289</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1755.1999.00521.x</pub-id><pub-id pub-id-type="pmid">10411705</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Hasselwander O, Savage DA, McMaster D, Loughrey CM, McNamee PT, Middleton D, et al. Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients. Kidney Int. 1999;56(1):289&#8211;98. 10.1046/j.1523-1755.1999.00521.x.<pub-id pub-id-type="pmid">10411705</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1523-1755.1999.00521.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirkham</surname><given-names>PA</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>PJ</given-names></name></person-group><article-title>Oxidative stress in COPD</article-title><source>Chest</source><year>2013</year><volume>144</volume><issue>1</issue><fpage>266</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1378/chest.12-2664</pub-id><pub-id pub-id-type="pmid">23880677</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Kirkham PA, Barnes PJ. Oxidative stress in COPD. Chest. 2013;144(1):266&#8211;73. 10.1378/chest.12-2664.<pub-id pub-id-type="pmid">23880677</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1378/chest.12-2664</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>F</given-names></name><name name-style="western"><surname>Hong</surname><given-names>W</given-names></name><name name-style="western"><surname>Zha</surname><given-names>R</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jin</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Smoking related attention alteration in chronic obstructive pulmonary disease-smoking comorbidity</article-title><source>BMC Pulm Med</source><year>2022</year><volume>22</volume><issue>1</issue><fpage>182</fpage><pub-id pub-id-type="doi">10.1186/s12890-022-01964-6</pub-id><pub-id pub-id-type="pmid">35524207</pub-id><pub-id pub-id-type="pmcid">PMC9078025</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Zeng F, Hong W, Zha R, Li Y, Jin C, Liu Y, et al. Smoking related attention alteration in chronic obstructive pulmonary disease-smoking comorbidity. BMC Pulm Med. 2022;22(1):182. 10.1186/s12890-022-01964-6.<pub-id pub-id-type="pmid">35524207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12890-022-01964-6</pub-id><pub-id pub-id-type="pmcid">PMC9078025</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>KF</given-names></name></person-group><person-group person-group-type="editor"><name name-style="western"><surname>Barnes</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Drazen</surname><given-names>JM</given-names></name><name name-style="western"><surname>Rennard</surname><given-names>S</given-names></name><name name-style="western"><surname>Thomson</surname><given-names>NC</given-names></name></person-group><article-title>Cytokines</article-title><source>Asthma and COPD: basic mechanisms and clinical management</source><year>2009</year><publisher-loc>London</publisher-loc><publisher-name>Academic Press</publisher-name><fpage>261</fpage><lpage>271</lpage></element-citation><mixed-citation id="mc-CR24" publication-type="book">Chung KF. Cytokines. In: Barnes PJ, Drazen JM, Rennard S, Thomson NC, editors. Asthma and COPD: basic mechanisms and clinical management. London: Academic Press; 2009. p. 261&#8211;71.</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Pei</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Oxidative DNA damage is involved in cigarette smoke-induced lung injury in rats</article-title><source>Environ Health Prev Med</source><year>2015</year><volume>20</volume><issue>5</issue><fpage>318</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1007/s12199-015-0469-z</pub-id><pub-id pub-id-type="pmid">25967734</pub-id><pub-id pub-id-type="pmcid">PMC4550611</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Chen Z, Wang D, Liu X, Pei W, Li J, Cao Y, et al. Oxidative DNA damage is involved in cigarette smoke-induced lung injury in rats. Environ Health Prev Med. 2015;20(5):318&#8211;24. 10.1007/s12199-015-0469-z.<pub-id pub-id-type="pmid">25967734</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12199-015-0469-z</pub-id><pub-id pub-id-type="pmcid">PMC4550611</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dizdaroglu</surname><given-names>M</given-names></name></person-group><article-title>Oxidative damage to DNA in mammalian chromatin</article-title><source>Mutat Res</source><year>1992</year><volume>275</volume><issue>3&#8211;6</issue><fpage>331</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1016/0921-8734(92)90036-o</pub-id><pub-id pub-id-type="pmid">1383774</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Dizdaroglu M. Oxidative damage to DNA in mammalian chromatin. Mutat Res. 1992;275(3&#8211;6):331&#8211;42. 10.1016/0921-8734(92)90036-o.<pub-id pub-id-type="pmid">1383774</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0921-8734(92)90036-o</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calder&#243;n-Garcidue&#241;as</surname><given-names>L</given-names></name><name name-style="western"><surname>Wen-Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Rodriguez-Alcaraz</surname><given-names>A</given-names></name><name name-style="western"><surname>Osnaya</surname><given-names>N</given-names></name><name name-style="western"><surname>Villarreal-Calder&#243;n</surname><given-names>A</given-names></name><etal/></person-group><article-title>8-hydroxy-2&#8242;-deoxyguanosine, a major mutagenic oxidative DNA lesion, and DNA strand breaks in nasal respiratory epithelium of children exposed to urban pollution</article-title><source>Environ Health Perspect</source><year>1999</year><volume>107</volume><issue>6</issue><fpage>469</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1289/ehp.107-1566580</pub-id><pub-id pub-id-type="pmid">10339447</pub-id><pub-id pub-id-type="pmcid">PMC1566580</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Calder&#243;n-Garcidue&#241;as L, Wen-Wang L, Zhang YJ, Rodriguez-Alcaraz A, Osnaya N, Villarreal-Calder&#243;n A, et al. 8-hydroxy-2&#8242;-deoxyguanosine, a major mutagenic oxidative DNA lesion, and DNA strand breaks in nasal respiratory epithelium of children exposed to urban pollution. Environ Health Perspect. 1999;107(6):469&#8211;74. 10.1289/ehp.107-1566580.<pub-id pub-id-type="pmid">10339447</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1289/ehp.107-1566580</pub-id><pub-id pub-id-type="pmcid">PMC1566580</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>HI</given-names></name><name name-style="western"><surname>Liou</surname><given-names>SH</given-names></name><name name-style="western"><surname>Ho</surname><given-names>SF</given-names></name><name name-style="western"><surname>Wu</surname><given-names>KY</given-names></name><name name-style="western"><surname>Sun</surname><given-names>CW</given-names></name><name name-style="western"><surname>Chen</surname><given-names>MF</given-names></name><etal/></person-group><article-title>Oxidative DNA damage estimated by plasma 8-hydroxydeoxyguanosine (8-OHdG): influence of 4, 4&#8242;-methylenebis (2-chloroaniline) exposure and smoking</article-title><source>J Occup Health</source><year>2007</year><volume>49</volume><issue>5</issue><fpage>389</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1539/joh.49.389</pub-id><pub-id pub-id-type="pmid">17951971</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Chen HI, Liou SH, Ho SF, Wu KY, Sun CW, Chen MF, et al. Oxidative DNA damage estimated by plasma 8-hydroxydeoxyguanosine (8-OHdG): influence of 4, 4&#8242;-methylenebis (2-chloroaniline) exposure and smoking. J Occup Health. 2007;49(5):389&#8211;98. 10.1539/joh.49.389.<pub-id pub-id-type="pmid">17951971</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1539/joh.49.389</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Deng</surname><given-names>K</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yao</surname><given-names>J</given-names></name><name name-style="western"><surname>Weng</surname><given-names>X</given-names></name><etal/></person-group><article-title>8-hydroxy-2&#8217;-deoxyguanosine as a biomarker of oxidative stress in acute exacerbation of chronic obstructive pulmonary disease</article-title><source>Turk J Med Sci</source><year>2019</year><volume>49</volume><issue>1</issue><fpage>93</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.3906/sag-1807-106</pub-id><pub-id pub-id-type="pmid">30762093</pub-id><pub-id pub-id-type="pmcid">PMC7350796</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Liu X, Deng K, Chen S, Zhang Y, Yao J, Weng X, et al. 8-hydroxy-2&#8217;-deoxyguanosine as a biomarker of oxidative stress in acute exacerbation of chronic obstructive pulmonary disease. Turk J Med Sci. 2019;49(1):93&#8211;100. 10.3906/sag-1807-106.<pub-id pub-id-type="pmid">30762093</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3906/sag-1807-106</pub-id><pub-id pub-id-type="pmcid">PMC7350796</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asami</surname><given-names>S</given-names></name><name name-style="western"><surname>Hirano</surname><given-names>T</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>R</given-names></name><name name-style="western"><surname>Tomioka</surname><given-names>Y</given-names></name><name name-style="western"><surname>Itoh</surname><given-names>H</given-names></name><name name-style="western"><surname>Kasai</surname><given-names>H</given-names></name></person-group><article-title>Increase of a type of oxidative DNA damage, 8-hydroxyguanine, and its repair activity in human leukocytes by cigarette smoking</article-title><source>Cancer Res</source><year>1996</year><volume>56</volume><issue>11</issue><fpage>2546</fpage><lpage>2549</lpage><pub-id pub-id-type="pmid">8653695</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Asami S, Hirano T, Yamaguchi R, Tomioka Y, Itoh H, Kasai H. Increase of a type of oxidative DNA damage, 8-hydroxyguanine, and its repair activity in human leukocytes by cigarette smoking. Cancer Res. 1996;56(11):2546&#8211;9.<pub-id pub-id-type="pmid">8653695</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MacNee</surname><given-names>W</given-names></name><name name-style="western"><surname>Tuder</surname><given-names>RM</given-names></name></person-group><article-title>New paradigms in the pathogenesis of chronic obstructive pulmonary disease I</article-title><source>Proc Am Thorac Soc</source><year>2009</year><volume>6</volume><issue>6</issue><fpage>527</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1513/pats.200905-027DS</pub-id><pub-id pub-id-type="pmid">19741262</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">MacNee W, Tuder RM. New paradigms in the pathogenesis of chronic obstructive pulmonary disease I. Proc Am Thorac Soc. 2009;6(6):527&#8211;31. 10.1513/pats.200905-027DS.<pub-id pub-id-type="pmid">19741262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1513/pats.200905-027DS</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tzortzaki</surname><given-names>EG</given-names></name><name name-style="western"><surname>Dimakou</surname><given-names>K</given-names></name><name name-style="western"><surname>Neofytou</surname><given-names>E</given-names></name><name name-style="western"><surname>Tsikritsaki</surname><given-names>K</given-names></name><name name-style="western"><surname>Samara</surname><given-names>K</given-names></name><name name-style="western"><surname>Avgousti</surname><given-names>M</given-names></name><etal/></person-group><article-title>Oxidative DNA damage and somatic mutations: a link to the molecular pathogenesis of chronic inflammatory airway diseases</article-title><source>Chest</source><year>2012</year><volume>141</volume><issue>5</issue><fpage>1243</fpage><lpage>1250</lpage><pub-id pub-id-type="doi">10.1378/chest.11-1653</pub-id><pub-id pub-id-type="pmid">22116800</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Tzortzaki EG, Dimakou K, Neofytou E, Tsikritsaki K, Samara K, Avgousti M, et al. Oxidative DNA damage and somatic mutations: a link to the molecular pathogenesis of chronic inflammatory airway diseases. Chest. 2012;141(5):1243&#8211;50. 10.1378/chest.11-1653.<pub-id pub-id-type="pmid">22116800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1378/chest.11-1653</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Hua</surname><given-names>DX</given-names></name><name name-style="western"><surname>Li</surname><given-names>MD</given-names></name><name name-style="western"><surname>Lv</surname><given-names>BB</given-names></name><name name-style="western"><surname>Fu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Serum 8-hydroxy-2&#8242;-deoxyguanosine predicts severity and prognosis of patients with acute exacerbation of chronic obstructive pulmonary disease</article-title><source>Lung</source><year>2022</year><volume>200</volume><issue>1</issue><fpage>31</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1007/s00408-021-00507-w</pub-id><pub-id pub-id-type="pmid">34982215</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Cao P, Zhang C, Hua DX, Li MD, Lv BB, Fu L, et al. Serum 8-hydroxy-2&#8242;-deoxyguanosine predicts severity and prognosis of patients with acute exacerbation of chronic obstructive pulmonary disease. Lung. 2022;200(1):31&#8211;9. 10.1007/s00408-021-00507-w.<pub-id pub-id-type="pmid">34982215</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00408-021-00507-w</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dos Santos</surname><given-names>CF</given-names></name><name name-style="western"><surname>Braz</surname><given-names>MG</given-names></name><name name-style="western"><surname>de Arruda</surname><given-names>NM</given-names></name><name name-style="western"><surname>Caram</surname><given-names>L</given-names></name><name name-style="western"><surname>Nogueira</surname><given-names>DL</given-names></name><name name-style="western"><surname>Tanni</surname><given-names>SE</given-names></name><etal/></person-group><article-title>DNA damage and antioxidant capacity in COPD patients with and without lung cancer</article-title><source>PLoS ONE</source><year>2022</year><volume>17</volume><issue>11</issue><fpage>e0275873</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0275873</pub-id><pub-id pub-id-type="pmid">36327269</pub-id><pub-id pub-id-type="pmcid">PMC9632772</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Dos Santos CF, Braz MG, de Arruda NM, Caram L, Nogueira DL, Tanni SE, et al. DNA damage and antioxidant capacity in COPD patients with and without lung cancer. PLoS ONE. 2022;17(11): e0275873. 10.1371/journal.pone.0275873.<pub-id pub-id-type="pmid">36327269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0275873</pub-id><pub-id pub-id-type="pmcid">PMC9632772</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ben Moussa</surname><given-names>S</given-names></name><name name-style="western"><surname>Sfaxi</surname><given-names>I</given-names></name><name name-style="western"><surname>Tabka</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ben Saad</surname><given-names>H</given-names></name><name name-style="western"><surname>Rouatbi</surname><given-names>S</given-names></name></person-group><article-title>Oxidative stress and lung function profiles of male smokers free from COPD compared to those with COPD: a case-control study</article-title><source>Libyan J Med</source><year>2014</year><volume>9</volume><issue>1</issue><fpage>23873</fpage><pub-id pub-id-type="doi">10.3402/ljm.v9.23873</pub-id><pub-id pub-id-type="pmid">24929061</pub-id><pub-id pub-id-type="pmcid">PMC4057786</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Ben Moussa S, Sfaxi I, Tabka Z, Ben Saad H, Rouatbi S. Oxidative stress and lung function profiles of male smokers free from COPD compared to those with COPD: a case-control study. Libyan J Med. 2014;9(1): 23873. 10.3402/ljm.v9.23873.<pub-id pub-id-type="pmid">24929061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3402/ljm.v9.23873</pub-id><pub-id pub-id-type="pmcid">PMC4057786</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nadeem</surname><given-names>A</given-names></name><name name-style="western"><surname>Raj</surname><given-names>HG</given-names></name><name name-style="western"><surname>Chhabra</surname><given-names>SK</given-names></name></person-group><article-title>Increased oxidative stress and altered levels of antioxidants in chronic obstructive pulmonary disease</article-title><source>Inflammation</source><year>2005</year><volume>29</volume><issue>1</issue><fpage>23</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1007/s10753-006-8965-3</pub-id><pub-id pub-id-type="pmid">16502343</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Nadeem A, Raj HG, Chhabra SK. Increased oxidative stress and altered levels of antioxidants in chronic obstructive pulmonary disease. Inflammation. 2005;29(1):23&#8211;32. 10.1007/s10753-006-8965-3.<pub-id pub-id-type="pmid">16502343</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10753-006-8965-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joppa</surname><given-names>P</given-names></name><name name-style="western"><surname>Petr&#225;sov&#225;</surname><given-names>D</given-names></name><name name-style="western"><surname>Stanc&#225;k</surname><given-names>B</given-names></name><name name-style="western"><surname>Dorkov&#225;</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tk&#225;cov&#225;</surname><given-names>R</given-names></name></person-group><article-title>Oxidative stress in patients with COPD and pulmonary hypertension</article-title><source>Wien Klin Wochenschr</source><year>2007</year><volume>119</volume><issue>13&#8211;14</issue><fpage>428</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1007/s00508-007-0819-y</pub-id><pub-id pub-id-type="pmid">17671825</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Joppa P, Petr&#225;sov&#225; D, Stanc&#225;k B, Dorkov&#225; Z, Tk&#225;cov&#225; R. Oxidative stress in patients with COPD and pulmonary hypertension. Wien Klin Wochenschr. 2007;119(13&#8211;14):428&#8211;34. 10.1007/s00508-007-0819-y.<pub-id pub-id-type="pmid">17671825</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00508-007-0819-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kluchov&#225;</surname><given-names>Z</given-names></name><name name-style="western"><surname>Petr&#225;&#353;ov&#225;</surname><given-names>D</given-names></name><name name-style="western"><surname>Joppa</surname><given-names>P</given-names></name><name name-style="western"><surname>Dorkov&#225;</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tk&#225;&#269;ov&#225;</surname><given-names>R</given-names></name></person-group><article-title>The association between oxidative stress and obstructive lung impairment in patients with COPD</article-title><source>Physiol Res</source><year>2007</year><volume>56</volume><issue>1</issue><fpage>51</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.33549/physiolres.930884</pub-id><pub-id pub-id-type="pmid">16497100</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Kluchov&#225; Z, Petr&#225;&#353;ov&#225; D, Joppa P, Dorkov&#225; Z, Tk&#225;&#269;ov&#225; R. The association between oxidative stress and obstructive lung impairment in patients with COPD. Physiol Res. 2007;56(1):51&#8211;6. 10.33549/physiolres.930884.<pub-id pub-id-type="pmid">16497100</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.33549/physiolres.930884</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gumral</surname><given-names>N</given-names></name><name name-style="western"><surname>Naziroglu</surname><given-names>M</given-names></name><name name-style="western"><surname>Ongel</surname><given-names>K</given-names></name><name name-style="western"><surname>Beydilli</surname><given-names>ED</given-names></name><name name-style="western"><surname>Ozguner</surname><given-names>F</given-names></name><name name-style="western"><surname>Sutcu</surname><given-names>R</given-names></name><etal/></person-group><article-title>Antioxidant enzymes and melatonin levels in patients with bronchial asthma and chronic obstructive pulmonary disease during stable and exacerbation periods</article-title><source>Cell Biochem Funct</source><year>2009</year><volume>27</volume><issue>5</issue><fpage>276</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1002/cbf.1569</pub-id><pub-id pub-id-type="pmid">19475625</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Gumral N, Naziroglu M, Ongel K, Beydilli ED, Ozguner F, Sutcu R, et al. Antioxidant enzymes and melatonin levels in patients with bronchial asthma and chronic obstructive pulmonary disease during stable and exacerbation periods. Cell Biochem Funct. 2009;27(5):276&#8211;83. 10.1002/cbf.1569.<pub-id pub-id-type="pmid">19475625</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cbf.1569</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahin</surname><given-names>U</given-names></name><name name-style="western"><surname>Unl&#252;</surname><given-names>M</given-names></name><name name-style="western"><surname>Ozg&#252;ner</surname><given-names>F</given-names></name><name name-style="western"><surname>S&#252;tc&#252;</surname><given-names>R</given-names></name><name name-style="western"><surname>Akkaya</surname><given-names>A</given-names></name><name name-style="western"><surname>Delibas</surname><given-names>N</given-names></name></person-group><article-title>Lipid peroxidation and glutathione peroxidase activity in chronic obstructive pulmonary disease exacerbation: prognostic value of malondialdehyde</article-title><source>J Basic Clin Physiol Pharmacol</source><year>2001</year><volume>12</volume><issue>1</issue><fpage>59</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1515/jbcpp.2001.12.1.59</pub-id><pub-id pub-id-type="pmid">11414508</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Sahin U, Unl&#252; M, Ozg&#252;ner F, S&#252;tc&#252; R, Akkaya A, Delibas N. Lipid peroxidation and glutathione peroxidase activity in chronic obstructive pulmonary disease exacerbation: prognostic value of malondialdehyde. J Basic Clin Physiol Pharmacol. 2001;12(1):59&#8211;68. 10.1515/jbcpp.2001.12.1.59.<pub-id pub-id-type="pmid">11414508</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1515/jbcpp.2001.12.1.59</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>ZJ</given-names></name><name name-style="western"><surname>Cai</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P</given-names></name></person-group><article-title>Oxidative stress links the tumour suppressor p53 with cell apoptosis induced by cigarette smoke</article-title><source>Int J Environ Health Res</source><year>2022</year><volume>32</volume><issue>8</issue><fpage>1745</fpage><lpage>1755</lpage><pub-id pub-id-type="doi">10.1080/09603123.2021.1910211</pub-id><pub-id pub-id-type="pmid">33825597</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Song Q, Zhou ZJ, Cai S, Chen Y, Chen P. Oxidative stress links the tumour suppressor p53 with cell apoptosis induced by cigarette smoke. Int J Environ Health Res. 2022;32(8):1745&#8211;55. 10.1080/09603123.2021.1910211.<pub-id pub-id-type="pmid">33825597</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/09603123.2021.1910211</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rao</surname><given-names>RS</given-names></name><name name-style="western"><surname>M&#248;ller</surname><given-names>IM</given-names></name></person-group><article-title>Pattern of occurrence and occupancy of carbonylation sites in proteins</article-title><source>Proteomics</source><year>2011</year><volume>11</volume><issue>21</issue><fpage>4166</fpage><lpage>4173</lpage><pub-id pub-id-type="doi">10.1002/pmic.201100223</pub-id><pub-id pub-id-type="pmid">21919202</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Rao RS, M&#248;ller IM. Pattern of occurrence and occupancy of carbonylation sites in proteins. Proteomics. 2011;11(21):4166&#8211;73. 10.1002/pmic.201100223.<pub-id pub-id-type="pmid">21919202</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pmic.201100223</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torres-Ramos</surname><given-names>YD</given-names></name><name name-style="western"><surname>Garc&#237;a-Guillen</surname><given-names>ML</given-names></name><name name-style="western"><surname>Olivares-Corichi</surname><given-names>IM</given-names></name><name name-style="western"><surname>Hicks</surname><given-names>JJ</given-names></name></person-group><article-title>Correlation of plasma protein carbonyls and C-reactive protein with GOLD stage progression in COPD patients</article-title><source>Open Respir Med J</source><year>2009</year><volume>3</volume><fpage>61</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.2174/1874306400903010061</pub-id><pub-id pub-id-type="pmid">19461898</pub-id><pub-id pub-id-type="pmcid">PMC2684712</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Torres-Ramos YD, Garc&#237;a-Guillen ML, Olivares-Corichi IM, Hicks JJ. Correlation of plasma protein carbonyls and C-reactive protein with GOLD stage progression in COPD patients. Open Respir Med J. 2009;3:61&#8211;6. 10.2174/1874306400903010061.<pub-id pub-id-type="pmid">19461898</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1874306400903010061</pub-id><pub-id pub-id-type="pmcid">PMC2684712</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mesia-Vela</surname><given-names>S</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>CC</given-names></name><name name-style="western"><surname>Austin</surname><given-names>JH</given-names></name><name name-style="western"><surname>Dounel</surname><given-names>M</given-names></name><name name-style="western"><surname>Powell</surname><given-names>CA</given-names></name><name name-style="western"><surname>Reeves</surname><given-names>A</given-names></name><etal/></person-group><article-title>Plasma carbonyls do not correlate with lung function or computed tomography measures of lung density in older smokers</article-title><source>Biomarkers</source><year>2008</year><volume>13</volume><issue>4</issue><fpage>422</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1080/13547500802002859</pub-id><pub-id pub-id-type="pmid">18484356</pub-id><pub-id pub-id-type="pmcid">PMC2692958</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Mesia-Vela S, Yeh CC, Austin JH, Dounel M, Powell CA, Reeves A, et al. Plasma carbonyls do not correlate with lung function or computed tomography measures of lung density in older smokers. Biomarkers. 2008;13(4):422&#8211;34. 10.1080/13547500802002859.<pub-id pub-id-type="pmid">18484356</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13547500802002859</pub-id><pub-id pub-id-type="pmcid">PMC2692958</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fireman</surname><given-names>KE</given-names></name><name name-style="western"><surname>Adir</surname><given-names>Y</given-names></name><name name-style="western"><surname>Krencel</surname><given-names>A</given-names></name><name name-style="western"><surname>Peri</surname><given-names>R</given-names></name><name name-style="western"><surname>Vasserman</surname><given-names>B</given-names></name><name name-style="western"><surname>Fireman</surname><given-names>E</given-names></name><etal/></person-group><article-title>Ultrafine particles in airways: a novel marker of COPD exacerbation risk and inflammatory status</article-title><source>Int J Chron Obstruct Pulmon Dis</source><year>2019</year><volume>14</volume><fpage>557</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.2147/COPD.S187560</pub-id><pub-id pub-id-type="pmid">30880945</pub-id><pub-id pub-id-type="pmcid">PMC6402613</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Fireman KE, Adir Y, Krencel A, Peri R, Vasserman B, Fireman E, et al. Ultrafine particles in airways: a novel marker of COPD exacerbation risk and inflammatory status. Int J Chron Obstruct Pulmon Dis. 2019;14:557&#8211;64. 10.2147/COPD.S187560.<pub-id pub-id-type="pmid">30880945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/COPD.S187560</pub-id><pub-id pub-id-type="pmcid">PMC6402613</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Isik</surname><given-names>B</given-names></name><name name-style="western"><surname>Ceylan</surname><given-names>A</given-names></name><name name-style="western"><surname>Isik</surname><given-names>R</given-names></name></person-group><article-title>Oxidative stress in smokers and non-smokers</article-title><source>Inhal Toxicol</source><year>2007</year><volume>19</volume><issue>9</issue><fpage>767</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.1080/08958370701401418</pub-id><pub-id pub-id-type="pmid">17613085</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Isik B, Ceylan A, Isik R. Oxidative stress in smokers and non-smokers. Inhal Toxicol. 2007;19(9):767&#8211;9. 10.1080/08958370701401418.<pub-id pub-id-type="pmid">17613085</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/08958370701401418</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watanabe</surname><given-names>J</given-names></name><name name-style="western"><surname>Kotani</surname><given-names>K</given-names></name><name name-style="western"><surname>Gugliucci</surname><given-names>A</given-names></name></person-group><article-title>Paraoxonase 1 and chronic obstructive pulmonary disease: a meta-analysis</article-title><source>Antioxidants</source><year>2021</year><volume>10</volume><issue>12</issue><fpage>1891</fpage><pub-id pub-id-type="doi">10.3390/antiox10121891</pub-id><pub-id pub-id-type="pmid">34942993</pub-id><pub-id pub-id-type="pmcid">PMC8750165</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Watanabe J, Kotani K, Gugliucci A. Paraoxonase 1 and chronic obstructive pulmonary disease: a meta-analysis. Antioxidants. 2021;10(12): 1891. 10.3390/antiox10121891.<pub-id pub-id-type="pmid">34942993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antiox10121891</pub-id><pub-id pub-id-type="pmcid">PMC8750165</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rumora</surname><given-names>L</given-names></name><name name-style="western"><surname>Rajkovi&#263;</surname><given-names>MG</given-names></name><name name-style="western"><surname>Kop&#269;inovi&#263;</surname><given-names>LM</given-names></name><name name-style="western"><surname>Pancirov</surname><given-names>D</given-names></name><name name-style="western"><surname>&#268;epelak</surname><given-names>I</given-names></name><name name-style="western"><surname>Grubi&#353;i&#263;</surname><given-names>T&#381;</given-names></name></person-group><article-title>Paraoxonase 1 activity in patients with chronic obstructive pulmonary disease</article-title><source>COPD</source><year>2014</year><volume>11</volume><issue>5</issue><fpage>539</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.3109/15412555.2014.898028</pub-id><pub-id pub-id-type="pmid">24831724</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Rumora L, Rajkovi&#263; MG, Kop&#269;inovi&#263; LM, Pancirov D, &#268;epelak I, Grubi&#353;i&#263; T&#381;. Paraoxonase 1 activity in patients with chronic obstructive pulmonary disease. COPD. 2014;11(5):539&#8211;45. 10.3109/15412555.2014.898028.<pub-id pub-id-type="pmid">24831724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/15412555.2014.898028</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gan</surname><given-names>WQ</given-names></name><name name-style="western"><surname>Man</surname><given-names>SF</given-names></name><name name-style="western"><surname>Senthilselvan</surname><given-names>A</given-names></name><name name-style="western"><surname>Sin</surname><given-names>DD</given-names></name></person-group><article-title>Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis</article-title><source>Thorax</source><year>2004</year><volume>59</volume><issue>7</issue><fpage>574</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1136/thx.2003.019588</pub-id><pub-id pub-id-type="pmid">15223864</pub-id><pub-id pub-id-type="pmcid">PMC1747070</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59(7):574&#8211;80. 10.1136/thx.2003.019588.<pub-id pub-id-type="pmid">15223864</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/thx.2003.019588</pub-id><pub-id pub-id-type="pmcid">PMC1747070</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>